Scott M. Dinehart

Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel

Brooke Bartley, Angela Rosenberg, Lauren DeBusk, Aaron S. Farberg et autres

BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) represents a significant clinical challenge in patients with locally advanced (laCSCC) or metastatic (mCSCC) disease who are not candidates for surgery or radiation. In addition to PD-1 inhibitors, pembrolizumab and cemiplimab, cosibelimab, a PD-L1 inhibitor, has …

Clinical and Molecular Effect of the Anti– IL ‐18 Antibody Aletekitug in Adults With Atopic Dermatitis

Joanne Ellis, Léa Fortunato, Hannah Wajdner, Ester Del Duca et autres

BACKGROUND: Interleukin-18 (IL-18) is a pleiotropic cytokine implicated in atopic dermatitis (AD), affecting both type (T)1 and T2 immune pathways. An anti-IL-18 monoclonal antibody, aletekitug, was evaluated for its clinical and molecular effects in patients with moderate to severe AD. METHODS: This …

gb, fr, us, ca (code pays fourni par la source)

Amélioration du prurit et des plaques/papules d’urticaire avec le rémibrutinib dès la première semaine de traitement des patients atteints d’urticaire chronique spontanée dans les études REMIX-1/-2

F. Bérard, Mark D. Scarupa, Scott M. Dinehart, Xiaosong Jiang et autres

fr, us, cn, gb, kr, ie, ch, ca (code pays fourni par la source)

A review of the safety, efficacy, and administration of hedgehog inhibitors for the treatment of advanced basal cell carcinoma: An expert consensus panel

Milaan Shah, Lauren DeBusk, Angela Easley Rosenberg, Joshua G. Burshtein et autres

BACKGROUND: Hedgehog inhibitors (HHIs) are approved for the treatment of locally advanced BCCs in patients who are not surgical candidates or have had recurrence following surgical treatment. This expert consensus panel further characterizes the efficacy and safety of HHIs while also providing …

us (code pays fourni par la source)

62280 Improvements in Itch and Hive Symptoms With Remibrutinib as Early as Week 1 in Patients With Chronic Spontaneous Urticaria (CSU) in REMIX-1/-2

Mark D. Scarupa, Scott M. Dinehart, Xian Li Jiang, Lindsey B. Finklea et autres

64631 Patient-Level Clinical Response Rates to GSK1070806, an Anti–IL-18 Monoclonal Antibody, in Moderate-to-Severe Atopic Dermatitis (AD): A Randomized, Double-Blind, Placebo-Controlled Study

John Francis Kelly, Léa Fortunato, J. R. Lowe, Scott M. Dinehart et autres

gb, us (code pays fourni par la source)

Efficacy and Safety of Hedgehog Inhibitors for Advanced Basal Cell Carcinoma: An Expert Consensus Panel

Joshua G. Burshtein, Milaan Shah, Danny Zakria, Scott M. Dinehart et autres

BACKGROUND: Hedgehog inhibitors (HHIs) can be used to treat patients with locally advanced basal cell carcinoma (laBCC) who are not candidates for surgery or radiation or whose tumors have recurred following radiation or surgery. The purpose of this expert consensus panel is …

Evidence-Based Consensus Recommendations for the Evolving Treatment of Patients with High-Risk and Advanced Cutaneous Squamous Cell Carcinoma

Guilherme Rabinowits, Michael Robert Migden, Todd E. Schlesinger, Robert Louis Ferris et autres

Cutaneous squamous cell carcinoma is the second most common skin cancer in the United States. Currently, there is no standardized management approach for patients with cutaneous squamous cell carcinoma who develop metastatic or locally advanced disease and are not candidates for curative …

us (code pays fourni par la source)

Treatment of Recalcitrant Prurigo Nodularis with Dupilumab

Matthew T Reynolds, Scott M. Dinehart, Katlyn R Anderson, Joe Gorelick

Objectives: Prurigo nodularis (PN) is a disease of aberrant and recalcitrant itching which is difficult to effectively manage. There are no current FDA-approved therapies for PN. The current topical and systemic medications used for this condition provide less than optimal efficacy for …

us (code pays fourni par la source)

Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management

Aaron S. Farberg, Mary A. Hall, Leah Douglas, Kyle R. Covington et autres

Objective: To integrate gene expression profiling into the management of high-risk cutaneous squamous cell carcinoma (cSCC) within the National Comprehensive Cancer Network (NCCN) guidelines to improve risk-aligned management recommendations.Methods: A cohort of 300 NCCN-defined high-risk cSCC patients, along with the American Joint …

us (code pays fourni par la source)

Immunohistochemistry utilization in the diagnosis of melanoma

Matthew S. Dinehart, Scott M. Dinehart, Suporn Sukpraprut‐Braaten, Whitney A. High

Abstract Background The use of immunohistochemical (IHC) stains in dermatopathology is commonplace; however, little is known regarding utilization trends in melanoma diagnosis. Current Medicare local coverage determinations (LCDs) state that most pigmented lesions, including melanoma, can be diagnosed using H&E alone. Methods …

us (code pays fourni par la source)

Multidisciplinary Expert-Driven Consensus on the Evolving Treatment of Patients with Advanced Cutaneous Squamous Cell Carcinoma

Michael Robert Migden, Todd E. Schlesinger, Chrysalyne Delling Schmults, Scott M. Dinehart et autres

Abstract not available.

us (code pays fourni par la source)